Text Size
Trial record 5 of 1806 for:    electrocardiogram
Previous Study | Return to List | Next Study

A Double-Blind Randomized Crossover Trial to Define the Electrocardiogram Effects of HPN-100

This study has been completed.
Sponsor:
Information provided by:
Hyperion Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01135680
First received: May 31, 2010
Last updated: November 8, 2010
Last verified: November 2010
History of Changes
  Purpose

Arm 1:

Primary Objective:

• To determine the safety and tolerability of multiple ascending, supratherapeutic doses of HPN-100.

Arm 2:

Primary Objective:

• To assess the effects of steady-state levels of HPN-100 metabolites (4 phenylbutyric acid [PBA], phenylacetic acid [PAA], and phenylacetylglutamine [PAGN]) on 12-lead electrocardiogram (ECG) parameters in healthy male and female subjects with the primary endpoint being the time-matched change from baseline in the QT interval corrected for heart rate (HR) based on an individual correction method (QTcI).


Condition Intervention Phase
Healthy Subjects
 Drug: HPN-100 or placebo
Drug: Placebo
Drug: Moxifloxacin
Drug: HPN-100
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Official Title: A Double-Blind Randomized Crossover Trial to Define the Electrocardiogram Effects of HPN-100 Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough Electrocardiogram Trial

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hyperion Therapeutics, Inc.:

Primary Outcome Measures:
  • The Electrocardiogram Effects of HPN-100 Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women. [ Designated as safety issue: No ]

Estimated Enrollment: 72
Study Start Date: May 2010
Arms Assigned Interventions
Placebo Comparator: Arm 1

Cohort A: 9 mL HPN-100 or placebo

Cohort B: 12 mL HPN-100 placebo

 Drug: HPN-100 or placebo
single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
Drug: HPN-100 or placebo
single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days
Placebo Comparator: Arm 2

This study requires 4 periods. In each of the periods you will receive one of the dose groups listed below. At the completion of the study you will have participated in all 4 dose groups. The order in which you participate in each dose group will be randomly assigned.

Dose Group A: 9 mL placebo via oral syringe 3 times daily for 3 days

Dose Group B: single oral dose of 400 mg moxifloxacin on study Day 3

Dose Group C: 6 mL HPN-100 and 3 mL placebo via oral syringe 3 times daily for 3 days

Dose Group D: 9 mL HPN-100 via oral syringe 3 times daily for 3 days

 Drug: Placebo
single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
Drug: Moxifloxacin
single oral 400-mg dose on study Day 3
Drug: HPN-100
single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
Drug: HPN-100
single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must be in good health
  • Negative hepatitis panel and negative HIV antibody screens
  • Females must be non-pregnant, non-lactating, and either postmenopausal or agree to to use adequate contraceptive methods throughout the study
  • Males must either be sterile or willing to use adequate contraceptive methods throughout the study
  • Willing and able to comply with all trial requirements
  • Able to comprehend and willing to sign an Informed Consent Form (ICF)

Exclusion Criteria:

  • History or clinical manifestations of significant allergic, metabolic, hepatic, renal, endocrine, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders
  • History of hypersensitivity or allergies to any drug compound
  • History of stomach or intestinal surgery or resection
  • History or presence of an abnormal ECG
  • History of alcoholism or drug addiction within 1 year
  • Use of any tobacco-containing or nicotine-containing products within 3 months
  • Participated in any other clinical trial of an investigational drug (or a medical device) within 30 days
  • Use of any prescription medications/products other than contraceptives within 14 days
  • Use of any over-the-counter, non-prescription preparations (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days
  • Test positive for drug(s) of abuse, ethanol, or cotinine
  • Have donated blood or blood components within 30 days
  • Have received blood products within 2 months
  • Have a history of unexplained syncope
  • Have a family history of unexplained sudden death
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01135680

Locations
United States, Wisconsin
Covance Clinical Pharmacology, Inc.
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
Hyperion Therapeutics, Inc.
  More Information

No publications provided

Responsible Party: Hyperion Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01135680     History of Changes
Other Study ID Numbers: HPN-100-010
Study First Received: May 31, 2010
Last Updated: November 8, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Contraceptives, Oral, Combined
 Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 19, 2013